scholarly journals Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV

2019 ◽  
Vol 55 (2) ◽  
pp. 1901259 ◽  
Author(s):  
Andrew D. Kerkhoff ◽  
Bianca Sossen ◽  
Charlotte Schutz ◽  
Elena Ivanova Reipold ◽  
Andre Trollip ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Point Of Care ◽  
Diagnostic Sensitivity ◽  
People Living With Hiv ◽  
Extra Pulmonary Tuberculosis ◽  
Urine Assay ◽  
Extra Pulmonary ◽  
Living With Hiv

scholarly journals Resurgence of Extra Pulmonary Tuberculosis

2016 ◽  
Vol 12 (1) ◽  
pp. 20-24
Author(s):  
S. Bag ◽  
N Deep ◽  
S Padhy
Keyword(s):  
Pulmonary Tuberculosis ◽  
Developing Nations ◽  
Hiv And Aids ◽  
People Living With Hiv ◽  
Extra Pulmonary Tuberculosis ◽  
Medical College ◽  
High Prevalence ◽  
Back Ground ◽  
Extra Pulmonary ◽  
Living With Hiv

Introduction: Pulmonary tuberculosis is a public health challenge in the developing Nations. Extra pulmonary tuberculosis (EPTB) is still more challenging. EPTB with co-infection with human deficiencies virus (HIV) and malnutrition further aggravate the problems, the worst human health scenario in 3rd world’s nation. The objective of the study was to explore the magnitude of Extra tuberculosis and to assess the challenge faced in encountering the patient with malnutrition, HIV infection etc.Method: All cases of tuberculosis registered under RNTCP in between 2009 - 2012 in MKCG Medical College, Berhampur, Odisha, India were scrutinized, 2596 case of EPTB were fished out. Details clinical, socio-economic, demographic, HIV status & treatment outcome of these patients were subjected to critical analysis.Results: Even though high prevalence of EPTB is encounter in poor socio-economic, rural back ground and people living with HIV and AIDS, upper and middle classes are not exempted complexities of diagnostic and therapeutic challenges are more often then not observed. Outcome is grim in immune weakened cases.Conclusion: This study emphasized the resurgence of extra pulmonary tuberculosis involving all classes of people in Indian sub-continent. Challenges faced are delineated and determinant of clinical outcome in developing Nations have been highlighted.SAARC J TUBER LUNG DIS HIV/AIDS, 2015; 12(1), Page: 20-24

Novel High Sensitivity Tuberculosis Point-of-Care Test for People Living with HIV

2018 ◽  
Author(s):  
Tobias Broger ◽  
Bianca Sossen ◽  
Elloise du Toit ◽  
Andrew D. Kerkhoff ◽  
Charlotte Schutz ◽  
...  
Keyword(s):  
Point Of Care ◽  
High Sensitivity ◽  
People Living With Hiv ◽  
Point Of Care Test ◽  
Living With Hiv

scholarly journals Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jill K. Gersh ◽  
Ruanne V. Barnabas ◽  
Daniel Matemo ◽  
John Kinuthia ◽  
Zachary Feldman ◽  
...  
Keyword(s):  
Pulmonary Tuberculosis ◽  
Preventive Therapy ◽  
World Health ◽  
People Living With Hiv ◽  
Tuberculosis Screening ◽  
Hiv Positive Adults ◽  
Health Organization ◽  
A Prospective Study ◽  
Living With Hiv ◽  
Tuberculosis Prevalence

Abstract Background People living with HIV (PLHIV) who reside in high tuberculosis burden settings remain at risk for tuberculosis disease despite treatment with anti-retroviral therapy and isoniazid preventive therapy (IPT). The performance of the World Health Organization (WHO) symptom screen for tuberculosis in PLHIV receiving anti-retroviral therapy is sub-optimal and alternative screening strategies are needed. Methods We enrolled HIV-positive adults into a prospective study in western Kenya. Individuals who were IPT-naïve or had completed IPT > 6 months prior to enrollment were eligible. We evaluated tuberculosis prevalence overall and by IPT status. We assessed the accuracy of the WHO symptom screen, GeneXpert MTB/RIF (Xpert), and candidate biomarkers including C-reactive protein (CRP), hemoglobin, erythrocyte sedimentation rate (ESR), and monocyte-to-lymphocyte ratio for identifying pulmonary tuberculosis. Some participants were evaluated at 6 months post-enrollment for tuberculosis. Results The study included 383 PLHIV, of whom > 99% were on antiretrovirals and 88% had received IPT, completed a median of 1.1 years (IQR 0.8–1.55) prior to enrollment. The prevalence of pulmonary tuberculosis at enrollment was 1.3% (n = 5, 95% CI 0.4–3.0%): 4.3% (0.5–14.5%) among IPT-naïve and 0.9% (0.2–2.6%) among IPT-treated participants. The sensitivity of the WHO symptom screen was 0% (0–52%) and specificity 87% (83–90%). Xpert and candidate biomarkers had poor to moderate sensitivity; the most accurate biomarker was CRP ≥ 3.3 mg/L (sensitivity 80% (28–100) and specificity 72% (67–77)). Six months after enrollment, the incidence rate of pulmonary tuberculosis following IPT completion was 0.84 per 100 person-years (95% CI, 0.31–2.23). Conclusions In Kenyan PLHIV treated with IPT, tuberculosis prevalence was low at a median of 1.4 years after IPT completion. WHO symptoms screening, Xpert, and candidate biomarkers were insensitive for identifying pulmonary tuberculosis in antiretroviral-treated PLHIV.

Sign in / Sign up

Export Citation Format

Share Document